Dominic E Sanford, Matthew R Porembka, Roheena Z Panni, Jonathan B Mitchem, Brian A Belt, Stacey M Plambeck-Suess, Goldie Lin, David G Denardo, Ryan C Fields, William G Hawkins, Steven M Strasberg, A Craig Lockhart, Andrea Wang-Gillam, Simon Peter Goedegebuure, David C Linehan
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by abundant granulocytic myeloid-derived suppressor cells (G-MDSC = CD45(+)/Lin(-)/CD33(+)/CD11b(+)/CD15(+)), which infiltrate tumors and suppress anti-tumor immunity. We have previously demonstrated in a murine model of PDAC that zoledronic acid (ZA) depletes G-MDSC resulting in decreased tumor growth and improved survival. We report here the results of a phase 1 clinical trial (NCT00892242) using ZA as neo-adjuvant, perioperative therapy in patients with non-metastatic, resectable pancreatic adenocarcinoma...
May 2013: Journal of Cancer Therapy